Bacitracin

Summary

Bacitracin is a cyclic peptide antibiotic belonging to the peptide‑antibiotic family. It is approved for over‑the‑counter use and marketed in several formulations, including topical ointments, ophthalmic drops, intramuscular injections and oral preparations. Clinically it is employed to treat skin and eye infections caused by susceptible Gram‑positive bacteria and is a component of combination products such as bacitracin‑colistin‑hydrocortisone ear drops.

Mechanism of Action

Bacitracin exerts its antibacterial effect primarily by targeting the bacterial cell membrane. It interferes with phospholipid biosynthesis and disrupts membrane integrity, leading to loss of the permeability barrier and inhibition of solute transport. In addition to this primary membrane‑targeting action, bacitracin can affect bacterial biofilms and down‑regulate virulence‑associated genes, providing secondary antimicrobial activity against Staphylococcus aureus and related organisms.

What the Research Shows

A 2023 review of membrane‑targeting antimicrobials lists bacitracin as a clinically used cyclic peptide that penetrates the Staphylococcus aureus membrane, inhibits phospholipid synthesis and blocks solute passage, with added effects on biofilm formation and virulence gene expression. Clinical evidence includes a 2024 randomized trial comparing hydrocortisone‑bacitracin‑colistin ear drops with oral amoxicillin for acute otitis media in children; the ear‑drop arm showed lower early symptom resolution and longer discharge, though it required fewer subsequent oral antibiotics and caused less gastrointestinal upset and rash. A 2019 review of systemic contact dermatitis notes bacitracin as a common topical sensitizer capable of provoking allergic reactions. Overall, the literature supports bacitracin’s membrane‑disrupting activity but highlights limited high‑quality clinical data for many indications.

Reported Benefits

Bacitracin provides effective topical coverage against susceptible Gram‑positive bacteria, making it useful for skin, eye and ear infections. Its membrane‑targeting mechanism may reduce the likelihood of rapid resistance development compared with some other agents. In the otitis media trial, the bacitracin‑containing ear drops were associated with fewer later oral antibiotic courses and a lower incidence of gastrointestinal upset and rash, suggesting a potential role in antibiotic‑sparing strategies.

Limitations of the Evidence

Robust comparative clinical trials are scarce; the ear‑drop study was under‑powered and could not confirm non‑inferiority to oral antibiotics. Evidence of efficacy is largely derived from in‑vitro studies and limited clinical reports. Bacitracin can provoke allergic contact dermatitis, restricting its use in sensitised individuals. Resistance patterns are not well characterized for many pathogens, and the drug is not approved for systemic infections beyond topical or intramuscular use.

Safety Considerations

Topical bacitracin is a frequent cause of allergic contact dermatitis, and systemic exposure can contribute to systemic contact dermatitis, a type 4 hypersensitivity reaction. Reported adverse effects include skin rash, itching and, in the ear‑drop trial, occasional rash. The ear‑drop formulation showed fewer gastrointestinal side effects than oral amoxicillin, but caution is advised in patients with known bacitracin allergy. Patch testing can aid diagnosis of bacitracin‑related dermatitis.

How It Is Administered

Bacitracin is available as a topical ointment or cream for skin infections, as an ophthalmic solution for eye infections, as an intramuscular injection for systemic use, and as an oral formulation. It is also combined with hydrocortisone and colistin in ear‑drop preparations for otitis media. Formulations are typically supplied in sterile containers appropriate for the intended route.

Routes of Administration

Goals & Uses

• Treatment of superficial skin infectionsAntimicrobialHigh
• Clostridium difficile infection (oral)Antimicrobial / GILow
• Systemic gram-positive infections (IM)Antimicrobial / SystemicLow
• Prevention of minor skin infectionAntimicrobial / Wound CareHigh
• Ophthalmic infections (conjunctivitis, blepharitis)Antimicrobial / OphthalmologyModerate
• treat superficial bacterial skin infectionsAntibacterialHigh

Contraindications

• hypersensitivity to bacitracinAllergyHigh
• Deep wounds, puncture wounds, or serious burns (OTC topical)Wound TypeModerate
• Severe renal impairment (systemic use)Organ ImpairmentModerate
• Known hypersensitivity to bacitracinAllergyHigh
• Renal impairment (systemic/IM use)RenalHigh

Adverse Effects

• AnaphylaxisImmunologicRareSevere life-threatening allergic reaction
• Contact dermatitis / Allergic sensitizationDermatologic / ImmunologicUncommon
• Contact dermatitisDermatologicalCommon
• Nausea/vomitingGastrointestinalRare
• Nausea and vomitingGastrointestinalUncommon
• Local injection site painLocal ReactionCommon
• Neuromuscular blockadeNeuromuscularRare
• NephrotoxicityRenalUncommon

Drug Interactions

• Loop diureticsLow
• Colistin / PolymyxinsModerate
• AminoglycosidesModerate
• Neuromuscular blocking agents (e.g., succinylcholine, vecuronium)High
• Other nephrotoxic agents (e.g., aminoglycosides, vancomycin, NSAIDs)High

Population Constraints

• PregnancyReproductive SafetyRelative
• Neonates (systemic use)PediatricRelative
• Patients with renal impairmentOrgan ImpairmentAbsolute
• Large surface area applicationSpecial UseRelative
• Pregnant womenReproductiveRelative
• NeonatesPediatricRelative

Regulatory Status

• European UnionApprovedApproved: topical treatment of minor skin infectionsAvailable as OTC ointment; systemic use restricted.
• United StatesApprovedApproved: topical treatment of minor skin infectionsOTC for topical formulations; intravenous use is investigational/compounded.
• United KingdomApprovedApproved: Topical skin and wound infections, Ophthalmic infectionsAvailable OTC and as prescription topical/ophthalmic preparations in the UK.

FDA-approved for topical and ophthalmic use OTC; intramuscular formulation is prescription-only and rarely used due to nephrotoxicity risk. Banned as a livestock feed additive in the EU. WHO classifies bacitracin as 'not critically important' for human medicine.

Evidence & Sources

• Antimicrobial Peptides and Small Molecules Targeting the Cell Membrane of Staphylococcus aureus
  Journal ArticleModerateGanesan N, et al.2023-01-01T00:00:00.000000Z
• Systemic Contact Dermatitis
  Journal ArticleModerateAquino M, Rosner G2019-01-01T00:00:00.000000Z
• Topical or oral antibiotics in childhood acute otitis media and ear discharge: a randomized controlled non-inferiority trial
  Journal ArticleModerateHullegie S, et al.2024-01-01T00:00:00.000000Z

Frequently Asked Questions